Mensur Zvekic, Maddie Herbert, Alba Morales, Samir Softic
Metabolic Dysfunction Associated Steatotic Liver disease is the most common cause of chronic hepatitis in children and adults. The patients with MASLD have low thyroid hormone activity in the liver. Recent evidence suggests that patients with MASLD may also have haptic growth hormone deficiency. Here, we present a case of a 13-year-old adolescent with obesity and short stature whose liver enzymes normalized with growth hormone therapy. The patient initially presented to the primary care physician's office, revealing a BMI in the 93rd percentile and elevated liver enzymes (ALT = 170 U/L, AST = 94 U/L). Subsequent visits showed a BMI in the 96th percentile, with further elevation in liver enzymes (ALT = 179 U/L, AST = 101 U/L). Following six months of lifestyle intervention, BMI decreased to the 91st percentile, and liver enzymes improved (ALT = 72 U/L, AST = 56 U/L), but did not normalize. Other causes of chronic hepatitis were excluded. Concurrently, screening for short stature revealed delayed bone age, although insulin-like growth factor 1 (IGF1) and insulin-like growth factor-binding protein 3 (IGFB3) levels were normal. Moreover, the patient failed a growth hormone (GH) stimulation test, revealing GH deficiency, corroborated by MRI findings of pituitary hypoplasia. GH therapy was initiated at pubertal doses. Nine months of GH therapy entirely normalized liver enzymes (ALT = 18, AST = 23), and BMI was reduced to the 75th percentile. GH therapy should be further investigated in adolescents with short stature and MASLD.
{"title":"Growth Hormone Treatment Normalized Liver Enzymes in an Adolescent with Obesity and Short Statute.","authors":"Mensur Zvekic, Maddie Herbert, Alba Morales, Samir Softic","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Metabolic Dysfunction Associated Steatotic Liver disease is the most common cause of chronic hepatitis in children and adults. The patients with MASLD have low thyroid hormone activity in the liver. Recent evidence suggests that patients with MASLD may also have haptic growth hormone deficiency. Here, we present a case of a 13-year-old adolescent with obesity and short stature whose liver enzymes normalized with growth hormone therapy. The patient initially presented to the primary care physician's office, revealing a BMI in the 93rd percentile and elevated liver enzymes (ALT = 170 U/L, AST = 94 U/L). Subsequent visits showed a BMI in the 96th percentile, with further elevation in liver enzymes (ALT = 179 U/L, AST = 101 U/L). Following six months of lifestyle intervention, BMI decreased to the 91st percentile, and liver enzymes improved (ALT = 72 U/L, AST = 56 U/L), but did not normalize. Other causes of chronic hepatitis were excluded. Concurrently, screening for short stature revealed delayed bone age, although insulin-like growth factor 1 (IGF1) and insulin-like growth factor-binding protein 3 (IGFB3) levels were normal. Moreover, the patient failed a growth hormone (GH) stimulation test, revealing GH deficiency, corroborated by MRI findings of pituitary hypoplasia. GH therapy was initiated at pubertal doses. Nine months of GH therapy entirely normalized liver enzymes (ALT = 18, AST = 23), and BMI was reduced to the 75th percentile. GH therapy should be further investigated in adolescents with short stature and MASLD.</p>","PeriodicalId":520084,"journal":{"name":"Annals of pediatrics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11373495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142135018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号